\
&
Contact us
\
&
Contact us
The European Commission has published guidelines on prohibited artificial intelligence (AI) practices, as defined by the EU AI Act. The guidelines provide an overview of AI practices that are considered unacceptable due to their potential risks to European values and fundamental rights. The AI Act, which aims to promote innovation while ensuring high levels of health, safety, and fundamental rights protection, classifies AI systems into different risk categories, including prohibited, high-risk, and those subject to transparency obligations. The guidelines specifically address practices such as harmful manipulation, social scoring, and real-time remote biometric identification. The guidelines aim to provide a consistent, effective and uniform application of the AI Act. They are non-binding, with authoritative interpretations reserved for the Court of Justice of the European Union (CJEU). The guidelines provide legal explanations and practical examples to help stakeholders understand and comply with the AI Act's requirements. It is important to note that at this stage, the Commission has approved the draft guidelines, but not yet formally adopted them. The guidelines can be found on the Commission website.
2025-02-05 Digital, Industry & Space Cybersecurity Defence EDFWe hereby want you to give an overview of the known activities related to the EDF 2025 calls: Publication of the European Defence Fund (EDF) Work Programme 2025 infosessions: Belgian and Flanders EDF infoday on February 21st in Brussels The EDF Info Days 2025 will take place on 2-3 April in hybrid format in Brussels and online - 🔗 Register Now SPACE 4 DEFENCE: European Defence Fund Industry & Matchmaking Day - Space4Defence 2025February 26th related training: Infosessions 'Strategic Goods Control department' (dCSG) on dual use and defence-related goodsseveral sessions between February 25th and november 20th further defence activity: Defence mission to Japan 202520-23 May
2025-02-04 Digital, Industry & Space AI, data & cloud Deployment: Best use of technologiesThe European Commission has published guidelines on prohibited artificial intelligence (AI) practices, as defined by the EU AI Act. The guidelines provide an overview of AI practices that are considered unacceptable due to their potential risks to European values and fundamental rights. The AI Act, which aims to promote innovation while ensuring high levels of health, safety, and fundamental rights protection, classifies AI systems into different risk categories, including prohibited, high-risk, and those subject to transparency obligations.The guidelines specifically address practices such as harmful manipulation, social scoring, and real-time remote biometric identification. The guidelines aim to provide a consistent, effective and uniform application of the AI Act. They are non-binding, with authoritative interpretations reserved for the Court of Justice of the European Union (CJEU). The guidelines provide legal explanations and practical examples to help stakeholders understand and comply with the AI Act's requirements. It is important to note that at this stage, the Commission has approved the draft guidelines, but not yet formally adopted them. The guidelines can be found on the Commission website.
2025-01-31 ERC MSCA RI Health Culture and societyDear users of the NCP Flanders website, As of today, the NCP Flanders website has a new look aimed at providing a more user-friendly experience. While the content and services available on the website remain unchanged, the fresh new layout is designed to enhance navigation and accessibility. Pages specifically related to one of the programmes we advise on can be easily identified by their colour: Blue for the framework programmes for research & innovation (Horizon Europe, Horizon 2020) Purple for Digital Europe Orange for Defence-related funding The different features such as news, events, info sheets, the video corner and partner searches remain the same and are still easy to find on the top of the page. We would also like to take this opportunity to invite you check and – if appropriate - update your profile to make sure that you receive information tailored to your specific needs.
2025-01-31 Digital, Industry & SpaceDistrict09 has currently a large satellite data-related tender outstanding, on behalf of the EUSPA-funded SPACE4Cities consortium. The Call for Tenders for SPACE4Cities was launched on 15 January 2025 and it will stay open until 9 April 2025. The tender forms, documents and other resources are now available. You can also check the LinkedIn post about available financing. This involves 2.87M€ million in R&D funding and they will select twenty different European companies or consortia focused on unlocking satellite data and services for better urban planning. Tendering Info Webinars The Info Webinar Series on SPACE4Cities 2.87M€ Call for Tenders focuses on providing information on the Pre-Commercial Procurement and tender submission process. You can participate in one or more webinars via the links below: Info Webinar February 26th, 2025 at 10:00–11:30 CET. Register here! Info Webinar March 25th, 2025 at 10:00–11:30 CET. Register here! Attached is the press release. You can sign up for the SPACE4Cities newsletter if you want to stay informed about the rest of this PCP.
Sign up for personalised information!
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you. By signing up, you can opt in for email notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Climate, Energy, Mobility EIC Digital Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
